Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Sunitinib 20Nivolumab 16cabozantinib 12Sorafenib 12pembrolizumab 11pazopanib 9Ipilimumab 9Interferon-alpha 9belzutifan 8Everolimus 8lenvatinib 7Bevacizumab 7aldesleukin 6Magnetic Resonance Spectroscopy 6Axitinib 6atezolizumab 5Interferon alpha-2 4temsirolimus 3Specimen Handling 3Radiosurgery 3Nephrectomy 3Interleukin-2 3tivozanib 2durvalumab 2avelumab 2Saline Solution 2G250 monoclonal antibody 2Fluorouracil 2Chemotherapy, Adjuvant 2CTLA-4 Antigen 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Renal Cell × abexinostat × Clear all
NCT03592472 2025-04-13

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Xynomic Pharmaceuticals, Inc.

Phase 3 Recruiting
413 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡